- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02225717
Identification of Spontaneous Delivery Markers (TrophY2)
Markers of Fetal Membranes Remodelling in Cervicovaginal Fluid and Delivery
The investigators project aims to identify, in pregnant women, discriminating molecules to allow an early detection of women who will spontaneously deliver prematurely, suitable in routine clinical practice.
Human parturition is tightly correlated with hormonal changes at the maternal-fetal interface during pregnancy, that may control cell interactions and fetal membranes (the water bag) remodelling. Precocious remodelling may lead to a premature onset of labor, associated or not with premature rupture of membrane whether the cause is infectious or not.
In this regard, remodelled fetal membranes overlying the cervix may discharge signals that could be detectable in cervico-vaginal fluids and serve as biomarkers of the imminence of delivery. Such information on delivery timing may be of great importance for an adequate prediction that would change drastically the management of threatening preterm delivery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prematurity is a major Public Health concern in developed countries, since it is the first cause of perinatal morbi-mortality and of cerebral palsy in early childhood. Premature birth rate has risen by 36 percent over the last 25 years to reach 7.2% in 2010 in France. Antenatal corticosteroids administration before 34 weeks and in utero transfer in high-qualified maternity wards are ones of the rare antenatal therapies recommended to improve neonatal complications of preterm delivery. Early identification of women with high risk of preterm birth should be helpful to implement those prophylactic measures. Moreover discriminating true preterm labor (PTL) vs. symptoms of PTL in women, who will finally deliver at term, would reduce unnecessary hospitalizations and prescriptions.
During human gestation, fetal membranes (the "water bag") encompass the amnion, facing the amniotic cavity, and the chorion, lining the maternal decidua and comprising trophoblast cells. Membranes usually remain intact until their spontaneous rupture, close to the first stage of labor at term. Often seen as a simple inert shell, with a role of "airbag" for the developing fetus, the membranes provide yet a large surface of interaction between maternal and fetal tissues and function as a transient endocrine organ with immune properties.
Specific remodelling of the membranes is observed at term prior to delivery. During this remodelling, drastic changes in extracellular matrix occur, with the secretion of specific molecules. The investigators hypothesize that premature fetal membranes remodelling occurs weeks prior to actual birth and may be able to be detected in women at risk for preterm birth, i.e. presenting signs of PTL. This study investigates if the detection of fetal membranes remodelling in cervico-vaginal fluids can accurately identify those women at greatest risk for preterm birth. A prospective cohort of pregnant women will before 32 weeks of gestation with symptoms of preterm labor be enrolled. As negative controls, healthy pregnant women at 12-15 or 35-36 weeks of gestation or non-pregnant women will be recruited. As positive controls, healthy pregnant woman at term (over 38 weeks of gestation) will be enrolled. The main outcome assessed is preterm delivery.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75014
- Maternité Port Royal-Cochin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Singleton pregnancy, monitored in Port Royal or secondarily transferred, between 24 and 32 GA. Hospitalization for preterm labor (cervix < 25 mm at transvaginal cervical ultrasound) or -Singleton pregnancy, monitered in Port Royal between 15-16 weeks of gestation, without complication.
or - Singleton pregnancy, monitered in Port Royal between 35-36 weeks of gestation, without complication.
or - Healthy woman, no pregnancy.
Exclusion Criteria:
- Minor
- Not affiliated to health insurance
- Persons under guardianship or judicial protection
- Infection with HIV, Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV)
- Diabetes or chronic inflammatory disease
- Carrier of B streptococcus
- Cervical strapping
- Fetus with chromosomal abnormalities
- Infections
- Premature rupture of membrane
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Non pregnant women
Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and >37 weeks of gestation and planed cesarean prior labor
|
Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter
|
|
Experimental: Preterm Labor
Pregnant women admitted for preterm labor
|
Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter
|
|
Experimental: Healthy pregnancy
Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and >37 weeks of gestation and planed cesarean prior labor
|
Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Delivery
Time Frame: until Day 14
|
Assessed among patients in preterm labor between 24 - 32 GA
|
until Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Delivery before 34 GA
Time Frame: until Day 14
|
Assessed among patients in preterm labor between 24 - 32 GA
|
until Day 14
|
|
composite Prenatal maternal care
Time Frame: until Delivery
|
Assessed by :
|
until Delivery
|
|
composite Neonatal outcome
Time Frame: At Birth
|
Assessed by :
|
At Birth
|
|
composite Obstetric outcome
Time Frame: At Delivery
|
Assessed by :
|
At Delivery
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Celine MEHATS, PhD, INSERM U1016 - Cochin Hospital Public Hospitals of Paris
Publications and helpful links
General Publications
- Larroque B, Ancel PY, Marret S, Marchand L, Andre M, Arnaud C, Pierrat V, Roze JC, Messer J, Thiriez G, Burguet A, Picaud JC, Breart G, Kaminski M; EPIPAGE Study group. Neurodevelopmental disabilities and special care of 5-year-old children born before 33 weeks of gestation (the EPIPAGE study): a longitudinal cohort study. Lancet. 2008 Mar 8;371(9615):813-20. doi: 10.1016/S0140-6736(08)60380-3.
- McLaren J, Malak TM, Bell SC. Structural characteristics of term human fetal membranes prior to labour: identification of an area of altered morphology overlying the cervix. Hum Reprod. 1999 Jan;14(1):237-41. doi: 10.1093/humrep/14.1.237.
- Malak TM, Bell SC. Structural characteristics of term human fetal membranes: a novel zone of extreme morphological alteration within the rupture site. Br J Obstet Gynaecol. 1994 May;101(5):375-86. doi: 10.1111/j.1471-0528.1994.tb11908.x.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P140502
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preterm Labor (24 GA - 32 GA)
-
University of PatrasUniversity Hospital of PatrasEnrolling by invitationPreterm Birth | Premature Baby 26 to 32 WeeksGreece
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; Institut... and other collaboratorsCompletedTerm and Preterm Neonates (24-41 Weeks Gestational Age) | Hematopoietic Stem Cell Transplant Recipient ChildrenFrance
-
Instituto de Investigacion Sanitaria La FeHospital Universitario La FeRecruitingVery Preterm Infants (<32 Weeks of Gestation)Spain
Clinical Trials on Cervicovaginal swab
-
Thomas Jefferson UniversityCompleted
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)RecruitingCervical Cancer | CIN2 | CIN3South Africa
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceCompletedInfertility | Human Papillomavirus (HPV) | Medically Assisted Procreation (MAP)France
-
Public Health EnglandCompletedNasal Carriage of PneumococciUnited Kingdom
-
LumiraDx UK LimitedCompleted
-
LumiraDx UK LimitedCompletedCOVID-19United States
-
University of VirginiaCompleted
-
University of Colorado, DenverGlaxoSmithKlineCompletedFever | Influenza | Otitis Media | Lower Resp Tract Infection | Encephalitic Infection | Myositis ViralUnited States
-
Medical University InnsbruckUnknown
-
Institut National de la Santé Et de la Recherche...CompletedInsufficient Intestinal Microbiota Diversity After C-section BirthFrance